Celiac Disease Research Center, Faculty of Medicine and Health Technology, Tampere University, FIN-33014 , Tampere, Finland.
Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
BMC Nephrol. 2022 Dec 8;23(1):395. doi: 10.1186/s12882-022-03019-8.
Gastrointestinal (GI) symptoms are common in end-stage kidney disease. Mounting evidence indicates that the intestine plays an important role in the pathogenesis of IgA nephropathy (IgAN). However, no studies have addressed the obvious question; do IgAN patients suffer from GI symptoms?
Presence of GI symptoms and health-related quality of life were evaluated using the validated Gastrointestinal Symptom Rating Scale (GSRS) and Psychological General Well-Being (PGWB) questionnaires in 104 patients with kidney biopsy-verified IgAN and in 147 healthy controls. A person was regarded to experience 'increased GI symptoms' if the GSRS score exceeded plus 1 standard deviation of the mean of the corresponding score in the healthy controls.
According to the GSRS total score, the IgAN patients had more GI symptoms than the healthy controls (2.0 vs. 1.7, p < 0.001). Female IgAN patients had higher GSRS total score than male patients (2.2 vs. 1.7, p = 0.001). More IgAN patients with preserved kidney function (eGFR > 60ml/min/1.73m) suffered from increased symptoms of diarrhoea (76 vs. 25%, p = 0.028), constipation (81 vs. 19%, p = 0.046) and reflux (85 vs. 15%, p = 0.004) than did IgAN patients with reduced kidney function (eGFR < 60ml/min/1.73m).
IgAN patients and especially female IgAN patients experienced more GI symptoms than healthy controls. More prevalent GI symptoms were already observed before kidney function was clearly reduced. Systematic enquiry of GI symptoms might increase the standard of care among IgAN patients. Moreover, GI symptoms may provide clues for future studies that examine the pathophysiology of IgAN.
胃肠道(GI)症状在终末期肾病中很常见。越来越多的证据表明,肠道在 IgA 肾病(IgAN)的发病机制中起着重要作用。然而,尚无研究探讨一个显而易见的问题,即 IgAN 患者是否存在胃肠道症状?
使用经过验证的胃肠道症状评分量表(GSRS)和心理一般健康问卷(PGWB)评估 104 例经肾活检证实的 IgAN 患者和 147 例健康对照者的胃肠道症状和健康相关生活质量。如果 GSRS 评分超过健康对照组相应评分的平均值加 1 个标准差,则认为个体存在“胃肠道症状增加”。
根据 GSRS 总分,IgAN 患者的胃肠道症状多于健康对照组(2.0 比 1.7,p<0.001)。女性 IgAN 患者的 GSRS 总分高于男性患者(2.2 比 1.7,p=0.001)。更多肾功能正常(eGFR>60ml/min/1.73m)的 IgAN 患者出现腹泻(76%比 25%,p=0.028)、便秘(81%比 19%,p=0.046)和反流(85%比 15%,p=0.004)等症状的比例高于肾功能下降(eGFR<60ml/min/1.73m)的 IgAN 患者。
IgAN 患者,尤其是女性 IgAN 患者,比健康对照组经历更多的胃肠道症状。在肾功能明显下降之前,就已经观察到更常见的胃肠道症状。系统询问胃肠道症状可能会提高 IgAN 患者的标准治疗水平。此外,胃肠道症状可能为未来研究 IgAN 病理生理学提供线索。